Clinical trials: Single Dose
Bioavailability and AUC
The Objective of This Study Was to Compare and Quantify the Bioavailability of Citrulline Byproducts in Blood Samples and in Urine Samples After a Single Dose of the Assigned Dietary Supplement. The Treatment Arms Containing the Following Molecules: Citrulline HCL and L-Citrulline,
Citrulline dietary supplements are of interest for improving cardiovascular and exercise performance. The health benefits of citrulline are attributable to its ability to increase arginine levels in the body through the…
- Trial name
- NCT06977854
- Testing
- Removal from study. In case of adverse event, subject treated for the AE., removal from study
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Vireo Systems, Inc.
Hematologic Malignancies
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with…
- Trial name
- NCT04588922
- Testing
- SLS009, venetoclax, azacitidine
- Where
- 32 sites in United States, China
- Volunteers
- 160 people
- Sponsor
- Sellas Life Sciences Group
Neoplasms, Non-small-cell Lung Cancer
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
The purpose of this study is to learn about the: safety (the effect of the study medicine on the participant's body), effects of the study medicine alone or in combination with sasanlimab - the best amount of the study medicine.
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
- Trial name
- NCT06546553
- Testing
- PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo)
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Alzheimer Disease
Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production
This is a Phase I, single center, open label, multiple dose, pharmacokinetic (PK) study recruiting healthy older subjects.
- Trial name
- NCT04268953
- Testing
- Tricaprilin
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Cerecin
Healthy Volunteers
A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese Subjects
The purpose of this study is to evaluate the pharmacokinetics and safety of ASP015K after single-dose and multiple-dose administration in healthy Chinese participants.
- Trial name
- NCT04143477
- Testing
- peficitinib
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma China, Inc.
Body Weight
Body Weight, Aspirin Dose and Pro-resolving Mediators
This study employs a placebo-controlled randomized cross-over design to investigate the impact of body weight and aspirin dose on levels of specialized pro-resolving lipid mediators in blood and neutrophils.
- Trial name
- NCT04697719
- Testing
- Aspirin 81mg, Aspirin 325mg
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Diabetes Mellitus, Type 2
First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.
The aim of this study is to assess how safe the study drug is and how well a participant tolerates it after a single oral (taken by mouth) dose.
- Trial name
- NCT03617081
- Testing
- NNC0113-2023
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy
Drug Interaction Study With Rifampicin and Afatinib
The objective of the current study is to investigate the effect of the P-gp inducer rifampicin on the pharmacokinetics (PK) of afatinib in healthy male volunteers
- Trial name
- NCT01396265
- Testing
- Afatinib, Rifampicin
- Where
- Germany
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Lymphoma, B-Cell Refractory
Exploration of Circular RNA in B-cell Hematologic Malignancies
This is an investigator-initiated, open-label, single-arm, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics (PD), and preliminary efficacy of an in vivo circular RNA chimeric…
- Trial name
- NCT07774572
- Testing
- Investigational product (IP)
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Healthy
Study of an Extended Release (ER) Tablet, Single and Repeated Dosing
The purpose is to study the safety and tolerability of increasing doses of AZD1305 and how the medication is metabolised by the body (how it is taken up, distributed, and how it disappears from the body).
- Trial name
- NCT00689039
- Testing
- AZD1305
- Where
- Sweden
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Adult Male and Female Volunteers
Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects
Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects
- Trial name
- NCT04341077
- Testing
- SHR3162
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
CABG, Coronary Artery Disease
Study of the Use of a Single Dose of Erythropoietin to Treat Acute Myocardial Ischemia
This is a phase 2 study that evaluates the effect of intravenous administration of a bolus EPO on the activation of EPOR-signal transduction cascades and myocardial apoptosis during cardiopulmonary bypass surgery.
- Trial name
- DREAM (NCT00524901)
- Testing
- Epoetin alpha, NaCl 0.9%
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- University Medical Center Groningen
Healthy
Pharmacokinetic Properties of Two Dosages Nevirapine Extended Release (XR) Formulations Compared to VIRAMUNE® Tablet as Well as to Nevirapine XR Tablet in Healthy Male Volunteers
Study to determine the pharmacokinetic properties of 200 mg (2 x 100 mg tablets once daily) and 300 mg (3 x 100 mg tablets once daily) Nevirapine extended release formulations and to estimate relative bioavailability of these…
- Trial name
- NCT02184312
- Testing
- Nevirapine XR low dose, Nevirapine XR medium dose, Nevirapine XR high dose
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Chronic Phase Ph+ Chronic Myeloid Leukemia
Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML
The goal of this observational study is to learn about the efficacy and safety profile when Radotinib dose redution is performed in Ph+ CML subjects. The main efficacy is checked by MMR rate by 12 months from IP treatment.
- Trial name
- NCT06665412
- Testing
- Radotinib Hydrochloride
- Where
- 2 sites in South Korea
- Volunteers
- 169 people
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Healthy
Study of ESBA105 Eye Drops in Healthy Subjects
Objectives: To evaluate the safety, tolerability and pharmacokinetics of ESBA105 administered topically to the eye for up to 28 days in healthy volunteers.
- Trial name
- NCT00671619
- Testing
- ESBA105
- Where
- Switzerland
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- ESBATech AG
Arthritis, Rheumatoid
Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid Arthritis (RA)
This study is designed to compare a range of doses of GW856553 versus placebo on the biomarkers associated with rheumatoid arthritis
- Trial name
- NCT00256919
- Testing
- GW856553
- Where
- 17 sites in Bulgaria, Germany and 3 more
- Volunteers
- 51 people
- Sponsor
- GlaxoSmithKline
Healthy
Single Dose Administration of Ketamine 10, 20, 40 and 80 mg and 5 mg Solution for Infusion in 15 Healthy Subjects
This study is designed for descriptive pharmacokinetic characterization of ketamine and norketamine in serum, urine and feces after oral single dose administration of a new developed prolonged release tablet formulation…
- Trial name
- NCT02494830
- Testing
- Ketamine
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
Healthy
Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults
The purpose of this study is to test the safety and tolerability of HFB30132A when it is given by intravenously to healthy participants.
- Trial name
- NCT04590430
- Testing
- HFB30132A
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- HiFiBiO Therapeutics
Healthy
Tolerability and Pharmacokinetics of BIIB 722 CL Drinking Solution and of BIIB 722 CL Filmcoated Tablet in Healthy Subjects
Safety and pharmacokinetics after oral single rising doses of BIIB 722 CL
- Trial name
- NCT02227030
- Testing
- BIIB 722 CL solution, BIIB 722 CL tablet
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Adult Participants
Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults
This is a single ascending dose study of L608 in healthy participants and is being conducted to evaluate the safety of L608 with dose level ranging from 10 μg to 20 μg.
- Trial name
- NCT06429930
- Testing
- L608 Liposomal inhalation suspension
- Where
- New Zealand
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pharmosa Biopharm Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.